Abstract: PROBLEM To provide a composition comprising highly enriched PUFA or its alkyl esters while containing fatty acid esters of 3-MCPD at adequately low concentrations and to provide an efficient method for producing the composition. MEANS FOR SOLVING A composition that contains fatty acids or fatty acid alkyl esters as its major component, the composition containing highly unsaturated fatty acid or alkyl ester thereof, wherein the proportion of the highly unsaturated fatty acid in the constituent fatty acids of the composition is 50 area % or more and wherein the concentration of 3-MCPD as found upon analyzing the composition by American Oil Chemists' Society official method Cd 29b-13 assay A is less than 1.80 ppm.

Abstract: Described herein are nutritional compositions, such as ketogenic compositions, leucine-enriched amino acid mixtures, etc., useful, for example, for dietary management of intractable epilepsy. In some embodiments, the disclosure relates to methods of inhibiting epileptic seizures in a subject comprising administering to the subject a leucine-enriched amino acid mixture.

Abstract: Provided is a method for purifying a phosphorus-containing olefin compound salt as a raw material or an intermediate that is useful to increase the purity of a target product in a method for producing an olefin compound and that can be applied to the production method, and a method for producing an olefin compound using a purified product obtained thereby.

Abstract: The present invention features novel peripherally-restricted isoguvacine analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.

Abstract: The use of a medicament as a single agent, binary agent, or other combination comprising of substantially pure novel cannabinoids 1 and 2, optionally admixed with one or more known and novel cannabinoids and other known naturally occurring and synthetic tetracyclic 2A and tricyclic 1A cannabinoids for the prevention, treatment or cure of inflammatory mediated diseases or inflammatory mediated pathological conditions, anorexia, arthritis, cancer, pain, glaucoma, migraine, persistent muscle spasms, seizures (epileptic seizures), severe nausea, PTSD, autism spectrum disorder, drug abuse, insomnia, or any other chronic or persistent medical symptom.

Abstract: The present invention relates to a process for the continuous synthesis of heavy alkyl acrylates by a transesterification reaction using hydrozincite as a heterogeneous catalyst.

Abstract: Agents containing either or both of aspartic acid and tyrosine are effective for improving intermittent endurance capacity.

Abstract: A method and system are disclosed for producing a protein and fiber feed product from a whole stillage byproduct produced in a corn dry milling process for making alcohol, such as ethanol, and/or other biofuels/biochemicals. In one embodiment, the method includes separating the whole stillage byproduct into an insoluble solids portion and a centrate (solubles) portion. Thereafter, a fine fiber and protein portion may be separated from the centrate (solubles) portion. The fine fiber and protein portion may be dewatered to provide a protein and fiber feed product. In one example, the protein and fiber feed product can include insoluble solids, such as wet or dry distiller's grains with or without solubles. The resulting protein and fiber feed product may be sold and/or used as rumen feed, swine feed, chicken feed, aqua feed, food uses, or have other uses, including pharmaceutical and/or chemical usage, for example.

Abstract: Docosahexaenoic acid-containing oil containing docosahexaenoic acid in a concentration of 40 wt. % or more of the total weight of fatty acids in the oil, and having an endothermic peak temperature determined by differential scanning calorimetry (DSC) of 15° C. or lower; a biomass including the same; and a method for producing docosahexaenoic acid-containing oil including obtaining a biomass by culturing microorganisms of the genus Aurantiochytrium capable of producing this docosahexaenoic acid-containing oil, recovering the biomass after culture, and extracting the oil from the biomass after recovery.

Abstract: This disclosure relates to methods and compositions for inhibiting release of extracellular vesicles from a cell infected by a virus. One aspect of the disclosure relates to methods for treating viral diseases, reducing damage to a neuron from the central neural system (“CNS”) and/or treating neuroinflammation in a subject. In another aspect, provided herein are methods for inhibiting transcription of a viral RNA and/or release of extracellular vesicles from a cell infected by a virus.

Abstract: A flavor composition comprising at least one compound that modulates, increases and/or enhances the activity of a GPR120 fatty acid receptor that can be used to enhance the fatty acid taste and/or palatability of pet food products is described herein. Also disclosed herein are methods for identifying said compounds.

Abstract: Disclosed herein are embodiments for the isolation of fiber and protein from brewers' spent grain. In some embodiments, the protein has a reduced fat content. In some embodiments, the protein has an improved Protein Digestibility Corrected Amino Acid Score.

Abstract: The present invention pertains to the field of maximizing performance of animals, particularly of pregnant animals and their offspring, particularly of pregnant sows and their offspring. Particularly the present invention is in the field of increasing the colostrum production of a sow, increasing average daily gain of the offspring, and/or improving neonatal survival of the offspring.

Abstract: Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.

Abstract: Embodiments of a method of purifying a lysophosphatidylcholine (e.g., LPC-DHA and/or LPC-EPA) from a composition containing the lysophosphatidylcholine and at least one impurity, e.g., from phospholipids, free fatty acids, triacylglycerols (TAGs), diacylglycerols (DAGs), monoacylglycerols (MAGs), glycerol, sterols, tocopherols, vitamin A, flavonoids, and minerals can use a continuous simulated moving bed process, a batch column chromatography method, or a single column to provide a purified composition of the lysophosphatidylcholine. The purified lysophosphatidylcholine (e.g., LPC-DHA and/or LPC-EPA) products can be used in various pharmaceutical and nutraceutical applications, e.g., for treating and/or preventing a neurological disease or disorder.

Abstract: The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.

Abstract: A method of extracting Polyhydroxylated Fatty Alcohols is disclosed. The method may include: inserting crushed avocado seeds to one or more extraction chambers; flowing supercritical CO2 fluid through the crushed avocado seeds in one or more extraction chambers; and separating from the supercritical CO2 flown through the crushed avocado seeds the Polyhydroxylated Fatty Alcohols extracted and dissolved in the supercritical CO2. The supercritical CO2 fluid may be the only solvent used for dissolving and extracting the Polyhydroxylated Fatty Alcohols.

Abstract: Provided herein is a class of ionizable lipid compounds represented by formula (IV), or pharmaceutically acceptable salts, isotopic variants, tautomers or stereoisomers thereof. Also provided is a nanoparticle pharmaceutical composition comprising said compound, and the application of said compound and its composition in the delivery of nucleic acids.

Abstract: The present invention relates to an isomerisation catalyst, in particular a zeolite catalyst. There is provided a method for making a particularly preferred zeolite catalyst by means of modifying catalytic zeolite materials. There is also provided a 5 process for isomerising fatty acids or alkyl esters thereof to produce branched fatty acids employing such an isomerisation catalyst, a composition comprising branched fatty acids, and also use of the isomerisation catalyst.

Abstract: The present disclosure relates to the preparation of a highly pure cannabidiol compound by a novel synthesis route. The cannabidiol compound can be prepared by an acid-catalyzed reaction of a di-halo olivetol with menthadienol, followed by two crystallization steps. The highly pure cannabidiol compound is produced in high yield, stereospecificity, or both, and shows exceedingly low levels of ?-9-tetrahydrocannabinol at the time of preparation and after storage.